1. Qiao, Han, Yin, Hong, Feng, Yan, Tang, Huaping. 2022. Pan-cancer analysis reveals the relationship between RCSD1 immune infiltration and clinical prognosis in human tumors. In Frontiers in immunology, 13, 1008778. doi:10.3389/fimmu.2022.1008778. https://pubmed.ncbi.nlm.nih.gov/36311703/
2. Kamran, Shawana, Raca, Gordana, Nazir, Kamran. 2015. RCSD1-ABL1 Translocation Associated with IKZF1 Gene Deletion in B-Cell Acute Lymphoblastic Leukemia. In Case reports in hematology, 2015, 353247. doi:10.1155/2015/353247. https://pubmed.ncbi.nlm.nih.gov/26600955/
3. Inokuchi, Koiti, Wakita, Satoshi, Hirakawa, Tsuneaki, Yamaguchi, Hiroki, Dan, Kazuo. 2011. RCSD1-ABL1-positive B lymphoblastic leukemia is sensitive to dexamethasone and tyrosine kinase inhibitors and rapidly evolves clonally by chromosomal translocations. In International journal of hematology, 94, 255-260. doi:10.1007/s12185-011-0910-z. https://pubmed.ncbi.nlm.nih.gov/21863287/
4. Mustjoki, Satu, Hernesniemi, Sari, Rauhala, Auvo, Lundán, Tuija, Porkka, Kimmo. . A novel dasatinib-sensitive RCSD1-ABL1 fusion transcript in chemotherapy-refractory adult pre-B lymphoblastic leukemia with t(1;9)(q24;q34). In Haematologica, 94, 1469-71. doi:10.3324/haematol.2009.008094. https://pubmed.ncbi.nlm.nih.gov/19794096/
5. Cui, Yajuan, Peng, Hongling. 2023. Imatinib and CAR T cell therapy enable sustained response in a young patient with refractory RCSD1-ABL1-positive acute lymphoblastic leukemia. In Annals of hematology, 103, 361-362. doi:10.1007/s00277-023-05489-8. https://pubmed.ncbi.nlm.nih.gov/37864715/
智鼠故事 
